Cancer Survivorship · Collection 06

They Saved My Life. Why Does Sex Hurt Now?

Sexual health after cancer treatment, and why surviving should not mean silently surrendering intimacy.

The clinical education

Finishing cancer treatment does not automatically restore sexual function.

“Cancer treatment can change sexual function. That does not make sexual pain an acceptable price of survival.”

Sexual health can change during treatment, soon after it ends, or later in survivorship. Some changes improve. Others persist or appear with time. A cancer diagnosis does not mean that every survivor will have sexual symptoms, and one person’s treatment experience cannot predict another’s. Cancer type, tumor biology, treatment, age, other health conditions, relationships, and the time since treatment all shape what may happen.

Treatments that save or prolong life can also alter hormones, vulvovaginal tissue, pelvic anatomy, nerves, pelvic-floor function, sexual response, body image, and a woman’s sense of intimacy. Possible contributors include chemotherapy-related ovarian insufficiency; ovarian suppression; aromatase inhibitors or other endocrine therapy; removal of the ovaries; hysterectomy or other pelvic surgery; pelvic radiation or vaginal brachytherapy; vulvar or vaginal procedures; scarring; fatigue; medication effects; fear of pain; and the emotional weight of cancer. These effects are possible, not inevitable.

“Finishing cancer treatment does not automatically restore sexual function.”

Breast cancer and endocrine therapy can change the tissue environment

Ovarian suppression and aromatase inhibitors can create profound estrogen deprivation. In some women, this contributes to genitourinary syndrome of menopause (GSM), with dryness, burning, irritation, tissue fragility, urinary symptoms, or pain with penetration. Chemotherapy, surgical removal of the ovaries, and natural menopause can also contribute.

Tamoxifen and aromatase inhibitors are not interchangeable. They affect estrogen signaling in different ways, and an individual’s tissue symptoms and cancer-related considerations may differ. A symptom is not enough to infer what a medication is doing or which treatment is appropriate. Do not stop, pause, or change endocrine therapy on your own. For the focused discussion of breast cancer, menopause symptoms, and treatment-specific hormone decisions, see Breast Cancer/Menopause Care.

Gynecologic cancer and pelvic treatment can leave distinct effects

Pelvic surgery may leave scars or adhesions, change sensation, or alter the shape, length, or support of pelvic structures. Hysterectomy does not automatically shorten the vagina; the effect depends on the procedure and healing. Removing both ovaries can bring on abrupt menopause. Pelvic external-beam radiation and vaginal brachytherapy may affect tissue elasticity and lubrication, and in some women lead to fibrosis, narrowing, shortening, or tenderness. Vulvar or vaginal surgery may change local anatomy or sensation. Some effects emerge months or years later, while many women have no significant late sexual effects.

These histories call for a tailored conversation. A survivor treated for breast cancer does not have the same tissue and anatomic risks as a survivor treated with pelvic radiation, and neither experience describes every woman with that cancer.

Pain after cancer treatment is not automatically “just dryness.”

Dryness and friction may be part of the problem, but pain can also involve GSM, fragile tissue, pelvic-floor muscle guarding or myofascial pain, fibrosis or scar tissue, vaginal stenosis or shortening after selected treatments, surgical change, a vulvar skin condition, neuropathic pain, deep pelvic pain, infection, or another treatment-specific effect. More than one mechanism can be present at once.

“Where it hurts matters.”

Vulvar or vestibular burning, pain at the opening, deeper vaginal or pelvic pain, pain focused around a scar, discomfort related to narrowing or shortening, and pain that lingers after sex each offer useful clues. Location helps guide an evaluation; it does not establish a diagnosis by itself.

GSM is one possible diagnosis, not a label for every symptom

GSM describes changes in the vulva, vagina, and lower urinary tract related to declining estrogen after menopause or another hypoestrogenic state. It can include dryness, burning, irritation, painful penetration, tissue fragility, and urinary symptoms. A cancer history changes the treatment conversation. It should not end the treatment conversation.

Systemic menopausal hormone therapy and low-dose local vaginal estrogen are different treatments with different purposes and exposure. Nonhormonal moisturizers and lubricants are options; other prescription local therapies have their own evidence, labeling, and cancer-specific considerations. In a survivor of an estrogen-dependent cancer, treatment depends on the cancer and its biology, current or planned endocrine therapy, the symptom and its impact, prior treatments, available alternatives, evidence limits, and the woman’s priorities. For selected women with persistent symptoms, clinicians may discuss low-dose vaginal estrogen through shared decision-making; for a woman taking an aromatase inhibitor, coordination with oncology is particularly important. No option is universally right or universally forbidden for every survivor.

Sexual function may also shift with fatigue, pain-related anticipation, desire or arousal changes, medications, body-image changes, and relationship stress. The full survivorship context is addressed in Whole-Woman Cancer Survivorship.

The StrongHer truth

“Cancer history changes the treatment conversation. It should not end the treatment conversation.”

A composite experience

“Everybody kept asking whether the cancer was gone. Nobody asked whether sex still hurt.”

This educational vignette combines experiences survivors commonly describe. It is not the story of one identifiable patient.

She is grateful to be alive. She may also be the woman whispering, “Why do I feel guilty even asking about this?” Her follow-up visits are full of scans, medication questions, and the next date to remember. She is relieved when the results are reassuring, yet the pain and unfamiliarity of her body do not disappear with a clear scan.

“I tried lubricant. It still hurts.” The opening may burn. Her vagina may feel shorter or different. Her body may tense before penetration because pain has become predictable. Her partner may be afraid of hurting her. She may not recognize her body after a mastectomy, reconstruction, scars, hair or body changes, an ostomy, or pelvic surgery. A change in desire or arousal can leave her wondering whether she has lost a part of herself.

Perhaps her oncologist said not to use estrogen. She heard that as “there is nothing else to do,” even though she was never told that systemic hormone therapy, low-dose local treatment, nonhormonal choices, physical therapy, pain care, and sexual support are separate conversations. Perhaps no one asked whether she wanted penetration, wanted help with pain, missed closeness, or had any interest in sexual activity right now.

“I’m grateful to be alive. Why do I feel guilty even asking about this?”
“I tried lubricant. It still hurts.”
“My vagina feels completely different.”
“I tense up before penetration because I know it’s going to hurt.”
“My partner is afraid of hurting me.”
“I don’t recognize my body.”
“My oncologist said not to use estrogen, so I assumed there was nothing else to do.”

“I survived cancer. I didn’t expect to lose this part of myself.”

Gratitude and grief can coexist. Relief and anger can coexist. A woman can be thankful for treatment and still mourn what it changed. She can want sex, not want sex, want intimacy without penetration, or be unsure. None of those answers makes her less grateful or less whole.

You are allowed to say it out loud

“You do not have to prove gratitude for survival by staying silent about quality of life.”

Dr. Rhaney’s perspective

“When a cancer survivor tells me sex hurts, her cancer history changes my differential. It does not make pain inevitable.”

My first responsibility is to understand what happened, what the symptom is like, and what matters to her now. Cancer history is essential clinical context, not a reason to stop asking questions.

I consider the cancer type and treatment history; hormone-receptor status when relevant; current endocrine therapy; natural or treatment-induced menopause; and any pelvic surgery, radiation, or brachytherapy. Then I ask where pain occurs, when it began, whether it is superficial or deep, how long it lasts, and what the woman has already tried. I also ask whether there is burning, bleeding, discharge, urinary change, a visible lesion, tissue sensitivity, scar tenderness, or a change in vaginal caliber or length.

The examination, if she wants one, is careful, trauma-informed, and paced for the patient. I explain each step before it happens, ask permission, offer choices about position and instruments, and stop or change course when she asks. A survivor remains in control of the examination. An internal examination is not a test she has to endure to prove that she deserves help.

Depending on her symptoms and preferences, assessment may include vulvar findings, tissue changes, scarring, vaginal length or caliber when relevant, pelvic-floor muscle tone and tenderness, sensation, and urinary symptoms. The goal is not to reproduce pain or force an examination. Sometimes the most useful next step is to treat what can be evaluated comfortably first and return to other questions only with the woman’s consent.

I hold more than one possibility in mind. GSM may be present, but I also consider pelvic-floor overactivity, scar-related restriction, radiation effects, infection, vulvar disease, neuropathic pain, deep pelvic conditions, medication effects, and the way fear after painful experiences can shape muscle response. These are not “all in her head.” Body, nervous system, treatment effects, and lived experience interact.

Finally, I ask what sexual function means to her now. Does she want less burning? Comfortable touch? A return to some form of sexual activity? Help talking with her partner? Relief from fear? Or simply to understand what has changed? Care should follow her goals, not a presumption that recovery means penetrative intercourse.

Clinical principle

“Where it hurts matters. Her treatment history matters. Her choices matter.”

The survivorship guide

Cancer history changes the treatment plan. It does not erase the treatment options.

Start with the mechanism and the cancer context. A treatment should answer the problem the woman actually has and support the goals she chooses.

Reduce friction when friction is part of the problem

A lubricant used during sexual activity can reduce friction. A vaginal moisturizer used regularly may ease everyday dryness for some women. More time for arousal, gentler pacing, changing activities, or stopping when something hurts may also help, if those choices fit the woman. Product choice can be individualized around sensitivity and the kind of sexual activity. Lubricant is useful for friction; it does not rebuild fragile tissue, lengthen a shortened vagina, release pelvic-floor guarding, or treat every pain condition.

Treat GSM thoughtfully

For GSM, regular nonhormonal moisturizers and lubricants are common starting points. If symptoms remain bothersome, prescription options may be considered according to the woman’s health and cancer history. Low-dose vaginal estrogen is a local treatment and is not the same as systemic menopausal hormone therapy. For survivors of estrogen-dependent cancer, the decision is individualized. A clinician should explain benefits, uncertainties, alternatives, endocrine therapy, and whether oncology collaboration would help. Other local prescription therapies, including vaginal DHEA or other options, have their own indications and evidence limits; “not estrogen” does not mean automatically suitable. See Breast Cancer/Menopause Care for breast-cancer-specific discussion.

Consider specialized pelvic-floor physical therapy

A pelvic-floor therapist with appropriate training may help when muscles guard, remain overactive, contribute to myofascial pain, or do not coordinate well. Therapy can address scar-related restriction, teach relaxation and coordination, and support a gradual return to comfortable activities when that is the woman’s goal. The plan may use education, breathing, external or internal manual techniques with consent, and individually selected exercises. Generic Kegels are not a universal answer; strengthening a muscle that is already guarding may not address the problem. The Vulvar Burning and Painful Sex collections discuss pelvic-floor pain care in more detail.

Use dilators or vaginal rehabilitation only with an individualized plan

After pelvic radiation, brachytherapy, selected operations, or when narrowing is present, a dilator may be part of a rehabilitation plan to maintain or work toward vaginal patency. It is not a command to “force the vagina open.” The clinician familiar with the cancer treatment should help determine whether it is appropriate, when to begin, what size and technique to use, how often, and what goal fits the woman’s anatomy and preferences. Painful or forceful use is not the measure of success. The goal is preservation or restoration of function suited to her medical situation and her own goals.

Evaluate scar, stenosis, and anatomic change directly

Selected survivors may need targeted evaluation for scar tissue, adhesions, vaginal narrowing or shortening, altered anatomy after surgery, or radiation-related fibrosis and tissue effects. The care plan should match the finding. A moisturizer alone cannot correct every anatomic restriction, and a dilator is not automatically the right response to every painful scar or tissue change.

Match persistent pain care to its mechanism

Persistent vulvar, pelvic-floor, neuropathic, scar-related, or deep pain may need a multimodal plan. That can involve pelvic-floor therapy, cause-specific medical treatment, pain-informed sexual counseling, or another specialist when appropriate. Explore Painful Sex and Vulvar Burning for deeper discussion of those pain pathways.

Address desire and arousal without reducing them to testosterone

Pain, ovarian suppression, endocrine therapy, treatment-induced menopause, fatigue, medication effects, body changes, mood, and the cancer experience can all affect desire or arousal. Low desire is not automatically a low-testosterone problem. Treating dryness or pain may remove a barrier to comfortable intimacy without directly creating desire. For a fuller conversation, see “I Love My Partner. So Why Don’t I Want Sex Anymore?”.

Intimacy does not require painful penetration

Sexual rehabilitation should not mean repeatedly doing something that hurts. While care is underway, a woman and a partner may choose touch, closeness, or other forms of intimacy that do not reproduce pain, or take a break from sexual activity. Penetrative intercourse is not the only measure of intimacy or sexual recovery. The right choice is the one that feels wanted, safe, and comfortable for her.

Make room for body image and identity

Mastectomy or reconstruction, scars, an ostomy, hair and body changes, pelvic surgery, or shifts in weight and body composition can alter how a woman experiences touch, desire, or her own reflection. This is more than a confidence problem. When helpful and wanted, psycho-oncology, sexual counseling, rehabilitation, peer support, or another clinician can be part of care. No one should be asked to feel a certain way on a timetable.

When sexual pain after cancer needs a closer look

Arrange an evaluation for new or worsening pain, unexplained bleeding, a new lesion or mass, persistent focal pain, significant tissue change, vaginal narrowing that prevents an examination or sexual activity the woman wants, persistent vulvar burning, new deep pelvic pain, unexplained discharge, symptoms that do not respond to appropriate care, or another change that concerns her in the context of her cancer history. Appropriate cancer-specific follow-up remains important. Do not assume that every new symptom is menopause or a treatment effect, and do not assume that every symptom means the cancer has returned.

A closer look is appropriate when symptoms change

New or persistent symptoms deserve an evaluation matched to the woman’s diagnosis, treatment, and follow-up plan. This is not a generic recurrence checklist. Her oncology team can advise when a finding needs cancer-specific assessment.

Myths that leave women without care

“I should just be grateful to be alive.” Gratitude and grief can live together. Wanting comfort and quality of life does not diminish survival.
“Painful sex is the price of cancer treatment.” Pain may be a treatment effect, but it is not an acceptable price women must silently pay. It deserves assessment and care.
“Lubricant is the only option.” Lubricant can reduce friction. GSM, muscle guarding, scar tissue, narrowing, and other pain mechanisms may need different approaches.
“If I had breast cancer, I can never use any vaginal hormonal therapy.” There is no single answer for every survivor. Nonhormonal measures are often tried first; persistent symptoms may lead to an individualized shared decision, particularly with oncology input during aromatase-inhibitor treatment.
“Vaginal estrogen and systemic hormone therapy are the same thing.” They are different routes and treatments with different purposes and exposure. Cancer-specific risks still require an honest individualized discussion.
“Dilators are supposed to hurt.” Force and pain are not goals. Timing, technique, and whether dilation is appropriate should be individualized with the treating team.
“If I don’t want penetration anymore, my sexual rehabilitation failed.” Recovery is not defined by penetration. The woman’s comfort, function, intimacy, and goals define the outcome.
“My oncologist didn’t bring it up, so it must not matter.” Sexual health is a legitimate part of survivorship care. It is appropriate to raise it with oncology, gynecology, urogynecology, or another trusted clinician.

What to bring to a visit

If it helps, jot down where pain occurs, when it began, whether it continues afterward, what kinds of touch or activity feel comfortable, any bleeding or urinary symptoms, cancer treatments and current medicines, and what you have already tried. You can also begin with one sentence: “I want to talk about sexual pain, and I need to stay in control of the conversation and examination.”

Important: This collection is educational and cannot diagnose the cause of an individual’s pain. Do not stop or change cancer treatment, endocrine therapy, or prescribed medication without discussing it with the clinicians who know your history.

Clinical review

Educational content reviewed September 2026 by Felicia L. Rhaney, MD, FACOG, MSCP. This material supports, but does not replace, individualized evaluation and care.

Selected guidance

Continue exploring

One topic. A fuller conversation.

Return to The Knowledge Hub

I survived cancer. I am still allowed to want comfort, intimacy, and a sexual life that belongs to me.